Shares of international drugmaker AstraZeneca have climbed more than 17% year to date, but a number of challenges lie ahead for the company. Despite bringing in a fresh management team last year and making acquisitions throughout 2013, it can take years to see tangible results in the pharmaceutical industry, and the turnaround at AstraZeneca is still unfolding.

In the following video, analyst Max Macaluso discusses the risks investors need to watch at AstraZeneca today, and focuses on three particular topics: revenue growth, its drug development pipeline, and acquisitions.

Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.